GANX

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Wall Street analysts forecast GANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GANX is 6.80 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Gain Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Gain Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -11.76 % YoY.

Gain Therapeutics Inc (GANX) has 23 emplpoyees as of December 15 2025.

Today GANX has the market capitalization of 159.23M USD.